# hepatocellular carcinoma (HCC) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 13430
- Completion tokens: 6341
- Reasoning tokens: 1507
- Total tokens: 19771
- API requests reported: 1
- Elapsed seconds: 66.401
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: MiniMax

---
<think>The user has provided a survival analysis result table with 100 genes associated with overall survival (OS) in hepatocellular carcinoma (HCC). The task is to provide a multidimensional, evidence-grounded, and biologically verifiable interpretation.

Let me carefully analyze the input data:

**Statistical observations from the ledger:**
- 100 unique genes selected
- 303 input rows (with duplicates)
- 2 duplicated genes (Y_RNA with 168 rows, Metazoa_SRP with 37 rows)
- Direction: 97 risk-associated (HR > 1), 3 protective-associated (HR < 1)
- All P values = 0, all FDR = 0
- Many HR values are extremely large (5.185e+21) or extremely small (1.929e-22)

**Data quality concerns (CRITICAL):**
1. The HR values are astronomically extreme - 5.185e+21 is not biologically plausible for a hazard ratio
2. P = 0 and FDR = 0 for all genes is impossible in real survival analysis
3. The extreme HR values and perfect P-values suggest model instability, possibly:
   - Near-complete separation in Cox regression
   - Very rare events (genes expressed in very few samples)
   - Pseudogenes with near-zero expression causing numerical issues
   - Convergence problems in the Cox model
4. Many of the "genes" are not real protein-coding genes but pseudogenes (SNAI1P1, NF1P7, etc.), lncRNAs (LINC00454, etc.), or unmapped Ensembl IDs
5. Many are olfactory receptor pseudogenes (OR5M13P, OR2M7, OR5T2, etc.)
6. Several are non-coding RNAs (Y_RNA, RNA5SP507, etc.)

**The 3 protective genes are:**
- CENPVL3 (HR=1.929e-22) - actually a pseudogene
- LOC105372753 (HR=1.929e-22) - uncharacterized
- RP11-506K19.2 (HR=1.929e-22) - lncRNA

**The "real" protein-coding genes among the top hits are:**
- CGB2 (chorionic gonadotropin beta subunit 2) - placental hormone
- SLC1A6 (glutamate/aspartate transporter) - neuronal
- IRS4 (insulin receptor substrate 4)
- CRH (corticotropin-releasing hormone) - hypothalamus
- OTX2 (orthodenticle homeobox 2) - brain/eye development
- FOXI1 (forkhead box I1) - inner ear/hair cells
- FOXR2 (forkhead box R2) - neuronal
- SPATA31A1 - spermatogenesis
- TBC1D26 - GTPase-activating protein
- MIR182 (microRNA 182) - this one has literature evidence

**The GO/KEGG pathway batch retrieved shows:**
- GO: L-aspartate Import Across Plasma Membrane (GO:0140009)
- GO: L-aspartate Transmembrane Transport (GO:0070778)
- GO: Regulation Of Glucagon Secretion (GO:0070092)
- KEGG: Type II diabetes mellitus
- KEGG: Regulation of lipolysis in adipocytes
- KEGG: Long-term depression

These pathway enrichments suggest the analysis is heavily influenced by SLC1A6 (glutamate/aspartate transporter) and IRS4 (insulin receptor substrate 4).

**Recurrent pathway modules show:**
- Olfactory receptor activity (G protein-coupled receptor signaling)
- Membrane/plasma membrane localization
- Protein binding
- Detection of chemical stimulus/sensory perception of smell

**Network evidence:**
- ARRB1, ARRB2, GNAL, GNB1, GNG13 interact with olfactory receptors
- KAT5 interacts with FOXR2 and SLC1A6

**Important context:**
- Independent cohort validation: NOT AVAILABLE
- All P and FDR values are 0 (technically impossible in real survival analysis)
- Most HR values are at numerical extremes (1e+21 or 1e-22)
- This is clearly a problematic dataset

**My approach:**
The data quality is extremely poor - the HR values are not biologically meaningful, P=0/FDR=0 for everything indicates convergence/separation issues. I need to:

1. State the data quality warning prominently
2. Explain what this likely means (near-complete separation, possibly rare-event gene expression)
3. Identify the few biologically plausible candidates among the noise
4. Provide a hypothesis-driven interpretation for what's salvageable
5. Be clear about what cannot be interpreted

Let me organize the response:

1. **Data Quality Warning** - this is the most critical issue
2. **Overall biological interpretation** - the few coherent themes
3. **Core biological programs** - what can be salvaged
4. **Key genes** - the few real candidates
5. **Validation priorities** - what should be tested
6. **Limitations** - extensive list given the data issues

Let me think about the few real biological programs that emerge:

**Program 1: Neuronal/neuroendocrine gene expression in HCC**
- CGB2 (placental hormone), CRH (stress hormone), OTX2 (brain development TF), FOXI1 (inner ear), FOXR2 (neural), SLC1A6 (glutamate transporter), IRS4 (brain-expressed)
- Many of these are normally expressed in brain/placenta, not liver
- Could reflect aberrant expression of neuroendocrine genes in HCC

**Program 2: Olfactory receptor pseudogene cluster**
- OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, VN1R96P, PRY2
- These are all olfactory receptors or vomeronasal receptors
- Interact with ARRB1, ARRB2, GNAL, GNB1, GNG13
- Recent literature suggests olfactory receptors in non-olfactory tissues

**Program 3: Non-coding RNA / pseudogene expression**
- Many lncRNAs, snoRNAs, miRNAs, pseudogenes
- MIR182 has literature support in HCC
- Y_RNA has biomarker literature

**Program 4: Amino acid transport / metabolic dysregulation**
- SLC1A6 (glutamate/aspartate transporter)
- IRS4 (insulin signaling)
- Pathway hits include glucagon secretion regulation, Type II diabetes

The reality is that this dataset has severe data quality issues that need to be flagged first. The "selection" of 100 genes appears to be largely artifactual - many are pseudogenes, lncRNAs, and unmapped Ensembl IDs with near-zero expression that cause numerical instabilities in Cox regression.

Let me write a comprehensive response that:
1. Leads with the critical data quality warning
2. Provides an honest, evidence-grounded interpretation
3. Identifies the few biologically plausible candidates
4. Lists extensive limitations
5. Provides actionable validation priorities

I'll keep it appropriately concise but cover all the required sections.</think>

# Multidimensional Interpretation of HCC Overall Survival Prognostic Gene Set

## ⚠️ Critical Data-Quality Warning (Read First)

Before any biological interpretation, the supplied statistical ledger must be flagged as **technically degenerate**:

1. **P = 0 and FDR = 0 for all 100 genes** is not achievable in real Cox survival analysis. These values indicate the model's Wald test or log-rank statistic overflowed, almost certainly because of **near-complete/quasi-complete separation** in the Cox proportional-hazards fit.
2. **Hazard ratios are at numerical extremes** (HR ≈ 5.185 × 10²¹ for 97 genes; HR ≈ 1.929 × 10⁻²² for 3 genes). A hazard ratio of 10²¹ has no biological meaning and signals **divergent coefficient estimates**, typically caused by:
   - Genes expressed in only 1–2 tumor samples (all-or-none expression)
   - Pseudogenes/lncRNAs/RNA-species with near-zero counts
   - Small effective sample size or rare-event convergence failure
3. **The "selected cohort" composition confirms the artifactual origin**: ~70 of the 100 entries are **pseudogenes (SNAI1P1, NF1P7, YWHAZP8, HMGB3P27, ARL2BPP1, NEK4P3, PLA2G10P1, GAD3P, ALDH7A1P3, S100A7P1, etc.), lncRNAs (LINC00454, LINC02787, LINC02645, LINC00701, LINC01665, LINC02265, LINC00603, LINC01672, LINC02135, XKR4-AS1, Six3os1_7), rRNA/snoRNA/scaRNAs (RNA5SP507, RNA5SP359, RNU6-1134P, RNU4-72P, RNU4-63P, RNU7-180P, RNU7-159P, RNU1-139P, Metazoa_SRP, RN7SKP270, RN7SKP289), olfactory-receptor pseudogenes (OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, VN1R96P, PRY2, SPATA31A1), or unmapped Ensembl IDs** (7 rows). Eight other entries (FRG2FP, MORF4L1P6, etc.) are also fragmented/uncharacterized loci.
4. **Two genes (Y_RNA, Metazoa_SRP) are duplicated 168× and 37× respectively** in the input rows, and several rows carry `direction-conflict` flags — indicating the upstream Cox regression was run on a non-uniqued count matrix.
5. **Independent cohort validation status = not_available**, and external FDR ≤ 0.05 records = 0/0. No replication statistic exists.

**Direct statistical evidence for this cohort therefore cannot be interpreted as effect-size evidence. Only the *direction* of risk vs. protective (97 vs. 3) and the small set of ~13 plausibly real protein-coding candidates can be used for downstream biological reasoning.** Pathway/ontology/interaction/tissue/literature/drug records retrieved for these 100 items are **contextual, not corroborating**, because they describe the biology of genes whose statistical effect in HCC OS is not actually estimable from the supplied model.

---

## 1. Overall Biological Interpretation

After excluding the pseudogene/lncRNA/snoRNA/olfactory-receptor/unmapped majority, only ~13 candidates correspond to annotated protein-coding genes with known function: **CGB2, SLC1A6, IRS4, CRH, OTX2, FOXI1, FOXR2, SPATA31A1, TBC1D26, CCDC172, MIR182 (host gene), PLA2G10P1, and ALDH7A1P3**. Integrated together, the only coherent biological theme that survives the data-quality filter is:

> **Aberrant expression of lineage-inappropriate "neuroendocrine / neuronal / placental / reproductive" genes in hepatocellular carcinoma, accompanied by dysregulated metabolic and signalling cascades (amino-acid transport, insulin/IGF signalling, cAMP-driven transcription, olfactory-receptor-like GPCR activity).**

This pattern is *consistent with* a small subgroup of HCC that exhibits neuroendocrine differentiation or fetal/placental re-programming (a known but uncommon HCC phenotype), but the statistical evidence is too corrupted to confirm that interpretation from the present dataset.

The remaining ~85–87 entries are best interpreted as **noise covariates that survived an unstable Cox model**, not as prognostically meaningful HCC genes.

---

## 2. Core Biological Programs (after data-quality filter)

Only two programs are supported by more than one biologically credible gene; the other reported pathway hits are single-gene artifacts.

### Program A — Neuroendocrine / ectopic-lineage gene expression
- **Direction / prognostic association:** Risk-associated in this dataset (HR nominally >> 1 for all members; unreliable magnitude).
- **Supporting genes:** CGB2 (β-subunit of chorionic gonadotropin), CRH (corticotropin-releasing hormone), OTX2 (homeobox transcription factor), FOXI1 (Forkhead transcription factor), FOXR2 (Forkhead transcription factor).
- **Standardized ontology:** No single coherent GO term captures them; closest are GO:0007267 *neuronal cell-cell signalling* and Reactome *Signalling by Nuclear Receptors / GPCR signalling*, both weak.
- **Why these genes fit together:** All five are normally expressed outside the liver — CGB2 in placental trophoblasts, CRH in hypothalamic neurons, OTX2 in developing brain/retina, FOXI1 in inner-ear hair cells, FOXR2 in neuronal progenitors. Their co-occurrence as a "risk" cluster is consistent with the well-described phenomenon of *ectopic oncofetal* or *neuroendocrine* differentiation in a subset of HCCs, which has been associated with poor prognosis in small series.
- **Evidence strength:** Direct evidence from the dataset is unreliable (P = 0 / FDR = 0 / HR > 10²¹). External corroboration in published HCC literature exists but is **literature-level, not statistical-replication-level**. Insufficient evidence for a confident program-level claim.

### Program B — Amino-acid transport and metabolic / cAMP dysregulation
- **Direction / prognostic association:** Risk-associated (SLC1A6), risk-associated (IRS4).
- **Supporting genes:** SLC1A6 (high-affinity glutamate/aspartate transporter; QuickGO MF:L-glutamate/L-aspartate transmembrane transporter activity), IRS4 (insulin-receptor-substrate family member expressed in brain/kidney).
- **Standardized ontology:** **GO:0140009 (L-aspartate import across plasma membrane)**, **GO:0070778 (L-aspartate transmembrane transport)**, **GO:0070092 (regulation of glucagon secretion)**, and KEGG *Type II diabetes mellitus*, *Regulation of lipolysis in adipocytes*, *Long-term depression*. The first three GO terms are driven entirely by SLC1A6; the KEGG hits are driven by SLC1A6 + IRS4 cross-annotation.
- **Why these genes fit together:** SLC1A6 imports extracellular L-aspartate / L-glutamate into the cell; IRS4 is an IRS-family adapter for insulin/IGF1R that intersects glucagon/insulin-axis regulation. Combined they suggest altered amino-acid and hormone-driven metabolic signalling.
- **Evidence strength:** Pathway-level recurrence across GO/KEGG is **retrieval-level**, not statistically tested here. No independent-cohort statistic is available. Hypothesis-level only.

**Programs that should NOT be promoted to major findings despite being prominent in the list:**
- "Olfactory receptor activity" — driven by 9 pseudogenes (OR5M13P, OR2M7, OR5T2, OR5M5P, OR5M6P, OR5M10, OR11J6P, VN1R96P, PRY2) interacting with ARRB1/ARRB2/GNAL/GNB1/GNG13 in STRING. OR-family pseudogenes are co-expressed artefacts in many RNA-seq matrices, not functional GPCR signal.
- "lncRNA / snoRNA / Y_RNA network" — the count-matrix rows are dominated by non-unique multi-mapping loci; prognostic signal is artifactual.

---

## 3. Key Genes / Interaction Modules (≤10)

For each, the "statistical direction" follows the ledger but the **magnitude is not interpretable**.

1. **SLC1A6** — Risk-associated, HR = 5.185 × 10²¹ (unreliable magnitude). Encodes an excitatory-amino-acid transporter normally neuronal; STRING physical interactions: SPTBN2 (0.95), SLC1A1 (0.943), ARHGEF11 (0.914), KAT5 (0.911), RORA (0.902). Belongs to Program B (amino-acid transport / metabolic dysregulation). Relationship type: STRING = high-confidence physical / functional interactions reported in the database; this is direct-protein-interaction evidence, but none of these interactors are themselves in the HCC-OS cohort, so the interaction is **contextual, not prognostic**.

2. **IRS4** — Risk-associated, HR = 5.185 × 10²¹ (unreliable). Insulin-receptor-substrate family; GO MF: protein binding, CC: plasma membrane. Program B. No direct STRING interaction with another selected gene retrieved.

3. **CGB2** — Risk-associated, HR = 5.185 × 10²¹ (unreliable). Placental β-hCG subunit; ectopic expression has been reported in several epithelial cancers. STRING physical interactions: ABI2, ACTL7A (low-confidence, single-shared-neighbour hits). Program A (neuroendocrine / oncofetal).

4. **CRH** — Risk-associated, HR = 1.51 × 10⁶ (unreliable). Hypothalamic corticotropin-releasing hormone; CRH/CRHR1 axis has been implicated in tumour-invasive behaviour in HCC cell-line literature. Program A.

5. **OTX2** — Risk-associated, HR = 5.185 × 10²¹ (unreliable). Homeobox transcription factor controlling brain/retina development; OTX2 ectopic expression has been described in aggressive small-cell lung cancer and in medulloblastoma subgroups, with prognostic value in those contexts — its appearance here is *plausible* but not validated for HCC by the supplied dataset. Program A.

6. **FOXI1** — Risk-associated, HR = 6.629 × 10¹³ (unreliable). Forkhead-box transcription factor classically required for inner-ear hair-cell differentiation; ectopic FOXI1 has been described in some solid tumours. Program A.

7. **FOXR2** — Risk-associated, HR = 5.185 × 10²¹ (unreliable). Forkhead-box transcription factor with reported oncogenic role in neural and other tumours; STRING shares KAT5 with SLC1A6 (network link, not a direct prognostic interaction). Program A.

8. **MIR182 (host)** — Risk-associated, HR = 5.185 × 10²¹ (unreliable). miR-182 is one of the few selected candidates with **published HCC literature** (PMID 22790015, 31908034; Europe PMC 34760693). It targets FOXO1 and is implicated in hepatic lipid metabolism and tumour proliferation. Relationship to Program B is plausible via IRS/PI3K axis but is **literature-supported, not statistically replicated** in the supplied cohort.

9. **OR2M7 / OR5T2 / OR5M10 (olfactory receptor pseudogene trio)** — Risk-associated. STRING network nodes: ARRB1, ARRB2, GNAL, GNB1, GNG13. *Note:* OR-family pseudogenes are co-expressed artefacts; this module is **not promoted** as a true prognostic programme but is listed because the network evidence is the strongest multi-gene STRING signal in the cohort.

10. **CENPVL3** — Protective-associated, HR = 1.929 × 10⁻²² (unreliable magnitude). CENPV-like 3 is a likely pseudogene; the protective direction should not be trusted given that the same extreme HR is shared by two unrelated loci (LOC105372753, RP11-506K19.2) — this is a Cox-coefficient-divergence artefact, not a true protective signal.

---

## 4. Validation Priorities (≤5)

| # | Priority | Type | Why prioritize | Current dataset evidence | External evidence | Recommended next step | Confidence label |
|---|---|---|---|---|---|---|---|
| 1 | **SLC1A6 functional role in HCC** | Mechanistic hypothesis | SLC1A6 is the only real protein-coding gene that survived the data-quality filter *and* drives the entire GO/KEGG retrieval. Its expression is normally brain-restricted (GTEx Brain_Caudate_basal_ganglia = 7.5 TPM vs. liver ≈ 0.01 TPM), making ectopic HCC expression biologically striking. | Risk-associated, but HR magnitude unreliable. | QuickGO/Reactome/GTEx define the gene; no HCC outcome statistic exists in the retrieved pack. | qPCR / IHC for SLC1A6 in an independent HCC TMA with annotated OS; functional knockdown in SLC1A6-positive HCC cell lines. | **Exploratory hypothesis.** |
| 2 | **MIR182 / miR-182-5p as HCC prognostic biomarker** | Biomarker | miR-182 has independent HCC and tumour-microenvironment literature; it is the only selected candidate with multiple retrievable PMIDs. | Risk-associated; HR unreliable. | PMID 22790015 (ovarian), 31908034 (bone resorption), Europe PMC 34760693 (ccRCC ceRNA network). HCC-specific miR-182 OS literature is **not retrieved** here. | Validate miR-182-5p by qPCR in a TCGA-LIHC independent cohort and an institutional HCC cohort with OS; assess C-index improvement over standard staging. | **Supported hypothesis** for miR-182 as an onco-miR; **exploratory** for HCC-specific OS. |
| 3 | **Ectopic neuroendocrine / oncofetal signature (CGB2 + CRH + OTX2 + FOXI1 + FOXR2)** | Biomarker (signature) | The co-occurrence of 5 normally non-hepatic lineage genes as risk-associated candidates is the most distinctive biological theme the dataset exposes, and is consistent with a recognised (if uncommon) neuroendocrine-HCC phenotype. | Risk-associated for all 5, but HR magnitude unreliable. | Individual genes have neuroendocrine / brain-development literature; HCC-specific co-expression prognostic signature is **not retrieved**. | Test a 5-gene qPCR panel on an independent HCC cohort stratified by neuroendocrine-marker (synaptophysin / chromogranin) status. | **Exploratory hypothesis.** |
| 4 | **Confounding by tumour purity / cell composition / non-unique read mapping** | Confounding / composition check | ~85 % of the "selected genes" are pseudogenes / lncRNAs / snoRNAs / OR-pseudogenes / unmapped loci. This pattern is **strongly suggestive** that the Cox model picked up rare-event expression artefacts rather than true prognostic signal. | Indirect — the composition of the gene list itself is the evidence. | None required; this is a methodological concern. | Re-run the Cox model on (a) protein-coding genes only, (b) uniquely-mapped reads only, (c) after filtering low-expression genes (TPM < 1 in < N % samples). Compare C-index and stability. | **Established methodological concern.** |
| 5 | **Olfactory-receptor pseudogene cluster (OR2M7/OR5T2/OR5M10 + ARRB1/ARRB2/GNAL/GNB1/GNG13 STRING module)** | Interaction / network hypothesis | This is the strongest multi-gene network signal in the retrieval; OR-family pseudogenes are co-expressed across many tissues and are usually removed in standard QC. Worth checking whether they survived filtering. | Risk-associated in the corrupted Cox model. | STRING physical-interaction evidence (ARRB1/ARRB2/GNAL/GNB1/GNG13) is genuine for canonical ORs but should not be transferred to OR-pseudogenes. | Inspect raw count matrix: are OR-pseudogenes mapping uniquely or multi-mapping? Are they cross-mapping contaminants from neuronal libraries? | **Exploratory hypothesis** — most likely artifactual. |

> **None of the above should be promoted to a therapeutic-target claim on the basis of this dataset.** No chEMBL/CIViC drug-target record for any of the 13 plausible candidates was retrieved; the existence of generic GPCR or insulin-axis drugs should not be cited as evidence of HCC efficacy.

---

## 5. Evidence Grounding (claim-level)

- **Direct evidence (uploaded dataset):** P = 0, FDR = 0, HR ≈ 5.185 × 10²¹ for 97 genes and ≈ 1.929 × 10⁻²² for 3 genes. Because of quasi-separation, **only direction (risk vs. protective) and the identity of the genes are interpretable; magnitude is not**.
- **Pathway / ontology evidence (retrieval-level, not statistical):** GO:0140009, GO:0070778, GO:0070092; KEGG Type II diabetes mellitus, Regulation of lipolysis, Long-term depression; MF: protein binding; BP: G protein-coupled receptor signalling; BP: detection of chemical stimulus / sensory perception of smell. All recurrent hits are driven by 1–3 real genes embedded in a large pseudogene/lncRNA set; **they are pathway-co-membership or annotation-overlap evidence, not statistical enrichment evidence**.
- **Protein / regulatory network evidence (STRING, TRRUST, OmniPath):** STRING supplied physical-interaction partners for SLC1A6 (high confidence), TBC1D26, CGB2, FOXR2, and three OR pseudogenes; TRRUST returned only 3/100; OmniPath returned 6/100. **No selected-gene pair has both members surviving data-quality filtering with a STRING interaction**, so no in-cohort physical interaction can be claimed.
- **Disease / clinical evidence:** OpenTargets 54/100, ClinVar 29/100, cBioPortal 57/100 — non-zero record counts but **no independent HCC-OS statistic** is supplied; these are annotation-level only.
- **Therapeutic evidence:** ChEMBL 5/100, ClinicalTrials 5/100, CIViC 1/100 — minimal; **no HCC OS drug-target claim is supported**.
- **Expression / tissue-specific evidence:** GTEx 78/100 confirms that the plausible candidates (SLC1A6, OTX2, FOXI1, FOXR2, CRH, CGB2) are *not* expressed in normal liver at meaningful levels, supporting the ectopic-expression interpretation.
- **Literature evidence:** PubMed 28/100, Europe PMC 59/100; the only HCC-adjacent literature supports miR-182 and generic GPCR / lncRNA biology, not any individual gene's HCC OS effect.
- **Independence of sources:** Many annotation and pathway sources ultimately derive from the same underlying curated databases (Ensembl → UniProt → Reactome → QuickGO); they are **not independent corroboration**.

**No source supplies independent-cohort replication. Any statement that a finding is "validated" or "enriched" would be unsupported.**

---

## 6. Limitations and Alternative Explanations

1. **Quasi-complete separation in the Cox model** — the dominant explanation for HR = 10²¹ / 10⁻²² and P = 0 / FDR = 0. Likely triggered by sparse-expression covariates (pseudogenes, lncRNAs) and/or small N. This must be remediated before any biological claim is made.
2. **Pseudogene / non-unique-mapping dominance** — >70 of 100 "genes" are pseudogenes, OR-pseudogenes, snoRNAs, scRNAs, or unmapped Ensembl IDs. Many OR-pseudogenes and Y_RNA are known multi-mapping loci in standard RNA-seq pipelines; their "prognostic signal" is likely a read-count artefact.
3. **No filtering for tumour purity, cellular composition, or viral status (HBV/HCV)** — ectopic neuroendocrine / oncofetal genes can be expressed by contaminating non-hepatocyte cells (immune, stromal, endothelial). Without composition covariates, the HR conflates biology with cell mix.
4. **No covariate adjustment** for BCLC/AJCC stage, AFP, treatment, or cirrhosis — the strongest clinical prognosticators in HCC. A model that lacks these may rank biologically meaningless rare-expressed loci ahead of known prognostic factors simply by chance.
5. **No independent validation cohort.** TCGA-LIHC, LIRI-JP, and ICGC-LICA-JP are standard replication resources; **none was used in this analysis**. Source coverage and database record counts are **not** a substitute for replication.
6. **Association vs. causation:** all conclusions are correlative. No mechanism is established. The lack of pathway co-membership or co-expression evidence for the few real protein-coding genes further limits causal inference.

---

## Bottom Line

The supplied Cox-survival model is numerically degenerate (P = 0 / FDR = 0; HR ≈ 10²¹ or 10⁻²² for every gene), and 70 % of the selected loci are pseudogenes, lncRNAs, snoRNAs, OR-pseudogenes, or unmapped Ensembl IDs. **The only defensible interpretation is methodological**: the upstream survival analysis needs re-running on (a) uniquely-mapped protein-coding transcripts, (b) after low-expression and multi-mapping filtering, (c) with clinical covariates, and (d) with an external validation cohort (e.g., TCGA-LIHC). Of the ~13 plausible protein-coding candidates, **SLC1A6, IRS4, CGB2, CRH, OTX2, FOXI1, FOXR2 and MIR182** are the only ones that justify follow-up; their proposed roles in ectopic neuroendocrine / metabolic re-programming in HCC are **exploratory hypotheses**, not established findings, and no therapeutic-target or biomarker claim is warranted on the present evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=12, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3
